As Biosimilars Gain US Traction, Patent Thickets Are Under More Scrutiny

Why It Matters

The move reshapes pricing dynamics by expanding affordable biologic alternatives, while tighter patent oversight could accelerate market entry and improve patient outcomes.

Key Takeaways

• Sun Pharma to spend $12 bn acquiring Organon for biosimilar expansion
• FDA has approved ~90 biosimilars, now 23% of US biologic market
• Patent thickets, like Humira’s 100+ patents, delay biosimilar entry
• New FDA guidance lowers clinical data requirements, easing biosimilar development
• Litigation expected to rise as more biosimilars target complex biologics

Pulse Analysis

The biosimilar segment in the United States is rapidly maturing, driven by both regulatory encouragement and commercial ambition. Sun Pharmaceutical’s $12 billion purchase of Organon signals the Indian giant’s intent to break into the top‑ten global biosimilar players, leveraging Organon’s established pipeline. Since the first FDA approval of a biosimilar in 2015, the agency has cleared roughly 90 products, which now represent about 23 % of the biologics market—a sizable jump from the early years. This momentum is reshaping pricing dynamics, offering insurers and patients cheaper alternatives to high‑cost biologics.

Yet the surge in biosimilar activity has exposed a persistent obstacle: patent thickets. Innovator firms often stack dozens, sometimes over a hundred, patents around a single biologic to extend market exclusivity, as seen with AbbVie’s Humira. Such dense patent portfolios can stall biosimilar entry for years, creating gaps of up to 16.5 years between brand expiration and competitor launch. Regulators, including the FDA, have begun questioning this practice, arguing it undermines the Biologics Price Competition and Innovation Act’s goal of fostering competition. Policy proposals aim to curb excessive patent layering without eroding legitimate innovation incentives.

The FDA’s latest guidance seeks to tip the balance toward faster, cheaper biosimilar development. By relaxing the clinical evidence threshold and allowing more streamlined data packages, the agency reduces trial costs and shortens timelines, especially for simpler molecules such as peptides and monoclonal antibodies. While the regulatory easing should boost the pipeline, it will not eliminate litigation; each new entrant is likely to face patent challenges and settlement negotiations. In the long run, the combined effect of lower development barriers and continued legal scrutiny could expand patient access while preserving a viable return on investment for innovators.